AIDS

1. VENTER F, Sokhela S, Calmy A, Siedner MJ, et al
   Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials.
   AIDS. 2022;36:1900-1901.
   

   >> Share

   
   
2. TARAMASSO L, Di Biagio A, Guaraldi G
   Response to: weight gain stopping/switch rules for antiretroviral clinical trials.
   AIDS. 2022;36:1899-1900.
   

   >> Share

   
   
3. AHLUWALIA AK, Inzaule S, Baggaley RC, Vitoria M, et al
   Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis.
   AIDS. 2022;36:1897-1898.
   

   >> Share

   
   
4. CARRARO A, Belvisi V, Garattini S, Cacace S, et al
   A case of primary central nervous system lymphoma in advanced naive HIV-infected patient: the role of antiviral agents.
   AIDS. 2022;36:1895-1896.
   

   >> Share

   
   
5. KOWALSKA JD, Rukhadze N, Sojak L, Bociaga-Jasik M, et al
   Preliminary report on the provision of HIV care to war refugees with HIV who are migrating from Ukraine: data from the ECEE Network Group.
   AIDS. 2022;36:1887-1890.
   

   >> Share

   
   
6. XIA Q, Edelstein ZR, Blumenthal JS
   Improving HIV preexposure prophylaxis implementation within healthcare settings.
   AIDS. 2022;36:1883-1885.
   

   >> Share

   
   
7. DUARTE FC, Moura LM, Laranjinha J
   High-level dolutegravir resistance can emerge rapidly from few variants and spread by recombination: implications for INSTI salvage therapy.
   AIDS. 2022;36:1881-1882.
   

   >> Share

   
   
8. LAEREMANS T, D'haese S, Aernout J, Barbe K, et al
   Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWH.
   AIDS. 2022;36:1761-1768.
   

   >> Share

   
   
9. SATISH S, Bravo L, McAllister A, Teitelman A, et al
   Provision of HIV pre-exposure prophylaxis to female patients seeking family planning services in the United States.
   AIDS. 2022 Sep 22. pii: 00002030-990000000-00119.
   

   >> Share

   
   
10. HAGENIMANA M, Kodan AE, George N, Businge L, et al
    Cancer in patients with and without HIV infection in the national cancer registry of Rwanda.
    AIDS. 2022 Sep 28. pii: 00002030-990000000-00120.
    

    >> Share

    
    
11. LUMU I, Musaazi J, Castelnuovo B
    Durability of switched therapy after failure of WHO-recommended antiretroviral therapy regimens in a resource-limited setting.
    AIDS. 2022;36:1791-1800.
    

    >> Share

    
    

    
    AIDS Res Hum Retroviruses

12. TAGLIAFERRI RAEL C, Giguere R, Sutton S, Horn E, et al
    Preferences for a Long-Acting, Removable Implant for HIV Prevention among MSM and Physicians: A Discrete Choice Study.
    AIDS Res Hum Retroviruses. 2022 Sep 30. doi: 10.1089/AID.2022.0035.
    

    >> Share

    
    
13. ZHAO R, Ma R, Zhao C, Zhang Q, et al
    Risk factors for Osteonecrosis of the femoral head in HIV positive patients: A retrospective case-control study.
    AIDS Res Hum Retroviruses. 2022 Sep 27. doi: 10.1089/AID.2021.0224.
    

    >> Share

    
    
14. SHARAFI M, Mirahmadizadeh A, Hassanzadeh J, Seif M, et al
    Prevalence of Late Presenters and Advanced HIV disease in HIV patients and their related factors in Iran: Results from 19 years of national surveillance HIV data.
    AIDS Res Hum Retroviruses. 2022 Sep 27. doi: 10.1089/AID.2022.0046.
    

    >> Share

    
    

    
    Ann Neurol

15. BOUMAZA X, Bonneau B, Roos-Weil D, Pinnetti C, et al
    Progressive multifocal leukoencephalopathy treated by immune checkpoint inhibitors.
    Ann Neurol. 2022 Sep 24. doi: 10.1002/ana.26512.
    

    >> Share

    
    

    
    BMC Immunol

16. POLLARA J, Khanal S, Edwards RW, Hora B, et al
    Single-cell analysis of immune cell transcriptome during HIV-1 infection and therapy.
    BMC Immunol. 2022;23:48.
    

    >> Share

    
    

    
    BMJ

17. WATERS L, Dewsnap C
    Young women and anal sex: healthcare professionals must normalise questions about what is normal for many people.
    BMJ. 2022;378:o2323.
    

    >> Share

    
    

    
    Clin Infect Dis

18. HARRISON TS, Lawrence DS, Mwandumba HC, Boulware DR, et al
    How applicable is the single-dose AMBITION regimen for HIV-associated cryptococcal meningitis to high-income settings?
    Clin Infect Dis. 2022 Sep 27. pii: 6724283. doi: 10.1093.
    

    >> Share

    
    

    
    HIV Med

19. LEVETT TJ, Vera JH, Jones CI, Bremner S, et al
    A cross-sectional assessment of frailty, falls and perceptions of ageing in people living with HIV using an mHealth platform.
    HIV Med. 2022 Sep 25. doi: 10.1111/hiv.13409.
    

    >> Share

    
    
20. FERREIRA AACM, Pinho RGG, de Aquino LM, de Barros Perini F, et al
    Disparities in HIV continuum of care in the paediatric population: A real-life study in Brazil.
    HIV Med. 2022 Sep 26. doi: 10.1111/hiv.13405.
    

    >> Share

    
    
21. RAYA RP, Curtis H, Kulasegaram R, Cooke GS, et al
    The British HIV Association national clinical audit 2021: Management of HIV and hepatitis C coinfection.
    HIV Med. 2022 Sep 29. doi: 10.1111/hiv.13417.
    

    >> Share

    
    
22. EPALZA C, Dominguez-Rodriguez S, Cervantes E, Jimenez de Ory S, et al
    Factors associated with late presentation for HIV care in adolescents in Spain.
    HIV Med. 2022 Sep 30. doi: 10.1111/hiv.13407.
    

    >> Share

    
    

    
    J Acquir Immune Defic Syndr

23. NEVREKAR N, Butler K, Shapiro DE, Atuhaire P, et al
    Self-Reported Antiretroviral Adherence: Association with Maternal Viral Load Suppression in Postpartum Women Living with HIV-1 from Promoting Maternal and Infant Survival Everywhere (PROMISE), a Randomized Controlled Trial in Sub-Saharan Africa and In
    J Acquir Immune Defic Syndr. 2022 Sep 28. pii: 00126334-990000000-00117.
    

    >> Share

    
    
24. CRANMER LM, Njuguna IN, LaCourse SM, Figueroa J, et al
    Performance of Tuberculosis symptom screening among hospitalized ART-naive Children with HIV in Kenya.
    J Acquir Immune Defic Syndr. 2022 Sep 26. pii: 00126334-990000000-00123.
    

    >> Share

    
    
25. WANG G, Song W, Rao S, Heitgerd J, et al
    HIV Positivity, Linkage to Medical Care, Interview for Partner Services, and Pre-exposure Prophylaxis Awareness and Referral among Men Who Have Sex with Men Tested in Non-healthcare Settings in the United States, 2019.
    J Acquir Immune Defic Syndr. 2022 Sep 26. pii: 00126334-990000000-00125.
    

    >> Share

    
    
26. VYAS KJ, Marconi VC, Moanna A, Rimland D, et al
    Trends in Cause-Specific Mortality among Veterans with HIV: A 35-Year (1982-2016) Analysis of the HIV Atlanta VA Cohort Study.
    J Acquir Immune Defic Syndr. 2022 Sep 26. pii: 00126334-990000000-00124.
    

    >> Share

    
    

    
    J Am Acad Dermatol

27. ALPALHAO M, Sousa D, Frade JV, Patrocinio J, et al
    Human Immunodeficiency Virus infection may be a contributing factor to Monkeypox infection: analysis of a 42-case series.
    J Am Acad Dermatol. 2022 Sep 22. pii: S0190-9622(22)02772.
    

    >> Share

    
    

    
    J Infect Dis

28. URIU K, Cardenas P, Munoz E, Barragan V, et al
    Characterization of the Immune Resistance of Severe Acute Respiratory Syndrome Coronavirus 2 Mu Variant and the Robust Immunity Induced by Mu Infection.
    J Infect Dis. 2022;226:1200-1203.
    

    >> Share

    
    

    
    J Med Virol

29. SHCHEMELEV AN, Boumbaly S, Ostankova YV, Zueva EB, et al
    Prevalence of drug resistant HIV-1 forms in patients without any history of ART in the Republic of Guinea.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28184.
    

    >> Share

    
    
30. HERMANUSSEN L, Grewe I, Tang HT, Norz D, et al
    Tecovirimat therapy for severe monkeypox infection: Longitudinal assessment of viral titers and clinical response pattern - A first case-series experience.
    J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28181.
    

    >> Share

    
    

    
    J Virol

31. NGUYEN HT, Kuse N, Zhang Y, Murakoshi H, et al
    Control of HIV-1 Replication by CD8(+) T Cells Specific for Two Novel Pol Protective Epitopes in HIV-1 Subtype A/E Infection.
    J Virol. 2022 Sep 26:e0081122. doi: 10.1128/jvi.00811.
    

    >> Share

    
    

    
    JAMA

32. KUEHN BM
    Interim Guidance for Monkeypox Among Patients With HIV.
    JAMA. 2022;328:1173-1174.
    

    >> Share

    
    

    
    Lancet Infect Dis

33. BAGCCHI S
    Global alliance to tackle HIV in children.
    Lancet Infect Dis. 2022;22:1426.
    

    >> Share

    
    
34. JIAN F, Yu Y, Song W, Yisimayi A, et al
    Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
    Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
    

    >> Share

    
    

    
    PLoS Med

35. GODFREY-FAUSSETT P, Frescura L, Abdool-Karim Q, Clayton M, et al
    HIV prevention for the next decade: Appropriate, person-centred, prioritised, effective, combination prevention.
    PLoS Med. 2022;19:e1004102.
    

    >> Share

    
    

    
    PLoS One

36. BAUMGARTNER JN, Nyambe N, Vasudevan L, Kasonde P, et al
    Prevalence of self-reported diabetes risk factors and integration of diabetes screening and referral at two urban HIV care and treatment clinics in Zambia.
    PLoS One. 2022;17:e0275203.
    

    >> Share

    
    
37. BOYCE CL, Beck IA, Styrchak SM, Hardy SR, et al
    Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
    PLoS One. 2022;17:e0275254.
    

    >> Share

    
    
38. STRAUSS MJ, Porter KD, Quizon PM, Davis SE, et al
    Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function.
    PLoS One. 2022;17:e0275182.
    

    >> Share

    
    
39. AGAMBIRE R, Mchunu GG, Naidoo JR
    Adolescent on the bridge: Transitioning adolescents living with HIV to an adult clinic, in Ghana, to go or not to go?
    PLoS One. 2022;17:e0273999.
    

    >> Share

    
    
40. MUTRICY-HUREAU L, Pisoni A, Suarez-Mutis M, Figueira da Silva A, et al
    Sexual and addictive risk behaviors and sexually transmitted infections in illegal gold miners in French Guiana: A multicenter observational study.
    PLoS One. 2022;17:e0272932.
    

    >> Share

    
    
41. BOLA R, Ujoh F, Lett R
    Identification and mitigation of high-risk pregnancy with the Community Maternal Danger Score Mobile Application in Gboko, Nigeria.
    PLoS One. 2022;17:e0275442.
    

    >> Share

    
    
42. KIYINGI J, Nabunya P, Bahar OS, Mayo-Wilson LJ, et al
    Prevalence and predictors of HIV and sexually transmitted infections among vulnerable women engaged in sex work: Findings from the Kyaterekera Project in Southern Uganda.
    PLoS One. 2022;17:e0273238.
    

    >> Share

    
    
43. CHOI WA, Sakeah E, Oduro AR, Aburiya JBA, et al
    Compliance to HIV testing and counseling guidelines at antenatal care clinics in the Kassena-Nankana districts of northern Ghana: A qualitative study.
    PLoS One. 2022;17:e0274871.
    

    >> Share

    
    
44. MUSSA FM, Massawe HP, Bhalloo H, Moledina S, et al
    Magnitude and associated factors of anti-retroviral therapy adherence among children attending HIV care and treatment clinics in Dar es Salaam, Tanzania.
    PLoS One. 2022;17:e0275420.
    

    >> Share

    
    
45. YIN O, Parikka N, Ma A, Kreniske P, et al
    Persistent anxiety among high school students: Survey results from the second year of the COVID pandemic.
    PLoS One. 2022;17:e0275292.
    

    >> Share

    
    
46. HLOPHE LD, Tamuzi JL, Shumba C, Nyasulu PS, et al
    Barriers to anti-retroviral therapy adherence among adolescents aged 10 to 19 years living with HIV in sub-Saharan Africa: A mixed-methods systematic review protocol.
    PLoS One. 2022;17:e0273435.
    

    >> Share

    
    

    
    PLoS Pathog

47. BOHM RP, Breed MW, Cohen JK, Haertel AJ, et al
    Formal Comment on "Mitigation of endemic GI-tract pathogen-mediated inflammation through development of multimodal treatment regimen and its impact on SIV acquisition in rhesus macaques" by Bochart et al. (2021).
    PLoS Pathog. 2022;18:e1010831.
    

    >> Share

    
    

    
    Vaccine

48. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share